This study aimed to show the effectiveness of interleukin (IL)‐23 inhibitors in psoriatic arthritis (PsA) at weeks 12 and 24 in a real‐world setting. Click to show full abstract
This study aimed to show the effectiveness of interleukin (IL)‐23 inhibitors in psoriatic arthritis (PsA) at weeks 12 and 24 in a real‐world setting.
               
Click one of the above tabs to view related content.